Treatment with ULBP2 CAR-T cells and anti-PD-1 showed remarkable antitumor efficacy, enhancing the survival of GC cell-line-derived xenografts (CDX) and GC patient-derived xenograft (PDX) mouse models. Here, ULBP2 is linked to gastric cancer.